|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: USP45 |
Gene summary for USP45 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | USP45 | Gene ID | 85015 |
| Gene name | ubiquitin specific peptidase 45 | |
| Gene Alias | LCA19 | |
| Cytomap | 6q16.2 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q70EL2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85015 | USP45 | NAFLD1 | Human | Liver | NAFLD | 1.14e-03 | 3.64e-01 | -0.04 |
| 85015 | USP45 | HCC1_Meng | Human | Liver | HCC | 2.12e-08 | -1.37e-02 | 0.0246 |
| 85015 | USP45 | HCC2_Meng | Human | Liver | HCC | 2.32e-04 | 1.46e-02 | 0.0107 |
| 85015 | USP45 | HCC1 | Human | Liver | HCC | 4.41e-02 | 1.75e+00 | 0.5336 |
| 85015 | USP45 | HCC2 | Human | Liver | HCC | 5.81e-04 | 1.22e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0070646 | Liver | NAFLD | protein modification by small protein removal | 29/1882 | 157/18723 | 9.11e-04 | 1.09e-02 | 29 |
| GO:0016579 | Liver | NAFLD | protein deubiquitination | 26/1882 | 139/18723 | 1.35e-03 | 1.52e-02 | 26 |
| GO:00706461 | Liver | HCC | protein modification by small protein removal | 91/7958 | 157/18723 | 6.50e-05 | 5.92e-04 | 91 |
| GO:00165791 | Liver | HCC | protein deubiquitination | 78/7958 | 139/18723 | 8.13e-04 | 4.87e-03 | 78 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| USP45 | SNV | Missense_Mutation | novel | c.1004A>C | p.Lys335Thr | p.K335T | Q70EL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.899) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| USP45 | SNV | Missense_Mutation | novel | c.2102N>A | p.Arg701Lys | p.R701K | Q70EL2 | protein_coding | tolerated(0.24) | probably_damaging(0.999) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| USP45 | SNV | Missense_Mutation | rs201236782 | c.2198N>G | p.Tyr733Cys | p.Y733C | Q70EL2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| USP45 | SNV | Missense_Mutation | c.520G>A | p.Glu174Lys | p.E174K | Q70EL2 | protein_coding | tolerated(0.13) | benign(0.036) | TCGA-BH-A18J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| USP45 | SNV | Missense_Mutation | c.654N>A | p.Met218Ile | p.M218I | Q70EL2 | protein_coding | tolerated(0.47) | benign(0.264) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| USP45 | SNV | Missense_Mutation | c.241N>C | p.Asp81His | p.D81H | Q70EL2 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| USP45 | insertion | Frame_Shift_Ins | novel | c.2212_2213insCCACCTCAGCCTCCCCAAGTGCTGAGAT | p.His738ProfsTer11 | p.H738Pfs*11 | Q70EL2 | protein_coding | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| USP45 | deletion | Frame_Shift_Del | novel | c.1522delN | p.Ser508GlnfsTer57 | p.S508Qfs*57 | Q70EL2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| USP45 | SNV | Missense_Mutation | novel | c.1001N>C | p.Arg334Thr | p.R334T | Q70EL2 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| USP45 | SNV | Missense_Mutation | novel | c.862N>T | p.Asp288Tyr | p.D288Y | Q70EL2 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |